Global Phase 3 Randomized Open-Label Study to Evaluate Efficacy & Safety of Firmonertinib Comp.w/ Osimertinib or Afatinib as 1st line Treat. in Pts. w/ Locally Advanced or Metastatic NSCLC with EGFR PACC Uncommon Mutations (Alpacca)
This is a Phase 3 study testing the safety and effectiveness of the new medicine firmonertinib (an EGFR-tyrosine kinase inhibitor) and comparing it with standard treatment medicines, such as osimertinib or afatinib (Targeted therapy), in patients with locally advanced or metastatic lung cancer that shows changes in EGFR PACC genes and who have not received any prior therapy for advanced disease. The study team will collect blood samples from all patients to see how they are doing. Special scans will be done for all patients to see how the study medicine is affecting their cancer and if the patients have a longer time before their cancer comes back. All patients will be closely monitored for potential side effects and safety concerns.
Glomerular Disease Program | NYU Langone Health
Doctors at the Glomerular Disease Program provide care for children at Hassenfeld Children’s Hospital at NYU Langone.
Glomerulonephritis in Children | NYU Langone Health
Doctors at Hassenfeld Children’s Hospital at NYU Langone diagnose and treat glomerulonephritis, a condition that causes kidney inflammation.
GLP-1 Agonist Treatment for Opioid Use Disorder - A Multi-Site Randomized Placebo-Controlled Trial
The purpose of this research study is to determine whether once-weekly treatment with an investigational drug, semaglutide, may help reduce illicit opioid use compared to placebo in individuals with opioid use disorder who are receiving either buprenorphine or methadone.
Gluten-Free Diet for Celiac Disease in Children | NYU Langone Health
Specialists at Hassenfeld Children’s Hospital at NYU Langone help children with celiac disease adapt to a gluten-free diet.
Glycemic and Cardiometabolic Biomarker improvements associated with reduction in air pollution exposure
In this research, we will conduct a double-blind, sham-controlled, randomized trial to examine the glycemic and cardiometabolic impact of air pollution exposure reduction using home portable air cleaners (PACs) in a cohort of 142 adult with prediabetes. This study will not evaluate the PAC or sham as medical devices in the context of this research; rather, the PAC and sham will be used per their commercialized indication as tools to standardize the conditions in order to measure the glycemic and cardiometabolic impact of reduced air pollution exposure.
Goal-Directed Cardiopulmonary Resuscitation in Cardiac Arrest Using a Novel Physiological Target: A Pilot Mechanistic Randomized Control Trial
The proposed study is a single-center, randomized controlled pilot trial of adults who suffer in-hospital cardiac arrests. Using cerebral oxygenation and end-tidal carbon dioxide physiological targets to predict survival and neurological outcome, the impact of physiological-feedback CPR will be assessed. 150 adult patients who have a cardiac arrest event at NYU Tisch Hospital will be randomized to one of two treatment groups: (1) Physiological-Feedback CPR or (2) Non-Physiological (Audiovisual) Feedback CPR.
Golf Lab | NYU Langone Health
The Golf Lab at NYU Langone’s Sports Performance Center helps golfers improve their game and avoid injury.
Gout Treatment Center | NYU Langone Health
Experts at NYU Langone’s Gout Treatment Center care for people with gout and other crystal-induced arthritis.
Gout Treatment Center Doctors | NYU Langone Health
Find a doctor at the Gout Treatment Center at NYU Langone.